Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Martino IST-Istituto Nazionale Tumori, Genoa, Italy.
Università degli Studi di Genova, Viale Benedetto XV, 6, 16132, Genoa, Italy.
J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.
SLFN11 is a recently discovered protein with a putative DNA/RNA helicase function. First identified in association with the maturation of thymocytes, SLFN11 was later causally associated, by two independent groups, with the resistance to DNA damaging agents such as topoisomerase I and II inhibitors, platinum compounds, and other alkylators, making it an attractive molecule for biomarker development. Later, SLFN11 was linked to antiviral response in human cells and interferon production, establishing a potential bond between immunity and chemotherapy. Recently, we demonstrated the potential role of SLN11 as a biomarker to predict sensitivity to the carboplatin/taxol combination in ovarian cancer. The present manuscript reports on the first international monothematic workshop on SLFN11. Several researchers from around the world, directly and actively involved in the discovery, functional characterization, and study of SLFN11 for its biomarker and medicinal properties gathered to share their views on the current knowledge advances concerning SLFN11. The aim of the manuscript is to summarize the authors' interventions and the main take-home messages resulting from the workshop.
SLFN11 是一种新发现的具有潜在 DNA/RNA 解旋酶功能的蛋白质。最初在胸腺细胞成熟过程中被发现，后来有两个独立的研究小组发现 SLFN11 与 DNA 损伤剂（如拓扑异构酶 I 和 II 抑制剂、铂化合物和其他烷化剂）的耐药性有关，这使得它成为生物标志物开发的有吸引力的分子。后来，SLFN11 与人细胞的抗病毒反应和干扰素产生有关，在免疫和化疗之间建立了潜在的联系。最近，我们证明了 SLN11 作为一种生物标志物预测卵巢癌对卡铂/紫杉醇联合化疗敏感性的潜力。本文报道了首次关于 SLFN11 的国际专题研讨会。来自世界各地的几位直接和积极参与 SLFN11 的发现、功能特征以及针对其生物标志物和药物特性进行研究的研究人员聚集在一起，分享他们对 SLFN11 的当前知识进展的看法。本文的目的是总结作者的干预措施以及研讨会得出的主要结论。
